1. Home
  2. ACRV vs ICG Comparison

ACRV vs ICG Comparison

Compare ACRV & ICG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.08

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Logo Intchains Group Limited

ICG

Intchains Group Limited

HOLD

Current Price

$0.98

Market Cap

59.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRV
ICG
Founded
2018
2017
Country
United States
China
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
74.0M
59.7M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
ACRV
ICG
Price
$2.08
$0.98
Analyst Decision
Buy
Strong Buy
Analyst Count
4
2
Target Price
★ $11.67
$5.25
AVG Volume (30 Days)
★ 295.2K
34.3K
Earning Date
05-08-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 15.13
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$568.17
N/A
P/E Ratio
★ N/A
$6.80
Revenue Growth
N/A
N/A
52 Week Low
$1.27
$0.60
52 Week High
$3.56
$2.28

Technical Indicators

Market Signals
Indicator
ACRV
ICG
Relative Strength Index (RSI) 54.90 52.27
Support Level $2.07 $0.81
Resistance Level $2.21 $1.04
Average True Range (ATR) 0.13 0.10
MACD 0.01 -0.01
Stochastic Oscillator 73.68 65.00

Price Performance

Historical Comparison
ACRV
ICG

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

About ICG Intchains Group Limited

Intchains Group Ltd is an inventive altcoins development company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies and the active development of inventive Web3 applications. The company offers high-performance mining products including altcoin mining machines incorporating its ASIC chips that have high computing power and superior power efficiency, ASIC chips and ancillary software and hardware, all of which cater to the evolving needs of the blockchain industry. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.

Share on Social Networks: